Krystal Biotech (KRYS) Net Margin (2023 - 2026)

Krystal Biotech has disclosed Net Margin across 4 years of filings, most recently posting 48.07% for Q1 2026.

• Net Margin for Q1 2026 came in at 48.07%, up 755.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 53.94% (up 1675.0% YoY), and the FY2025 annual result was 52.64%, up 2195.0% from the prior year.
• Net Margin came in at 48.07% for Q1 2026 at Krystal Biotech, roughly flat from 47.99% in the prior quarter.
• In the past five years, Net Margin ranged from a high of 943.75% in Q3 2023 to a low of 2.06% in Q1 2024.
• The 4-year median for Net Margin is 40.52% (2025), against an average of 120.79%.
• Across the five-year window, Net Margin plunged 91133 bps in 2024 and soared 4873 bps in 2025, its largest moves.
• Krystal Biotech's Net Margin stood at 20.63% in 2023, then surged by 142 bps to 49.95% in 2024, then fell by 4 bps to 47.99% in 2025, then rose by 0 bps to 48.07% in 2026.
• The last three Net Margin figures came in at 48.07% (Q1 2026), 47.99% (Q4 2025), and 81.15% (Q3 2025), per Business Quant data.